WALTHAM, Mass., April 3, 2008 Decision Resources, one ofthe world's leading research and advisory firms focusing on pharmaceutical andhealthcare issues, forecasts that the Chinese gastric cancer drug market willnearly triple between 2007 and 2012. According to the new Emerging Marketsreport entitled Gastric Cancer in China, this growth will be fueled byincreased access to health insurance and greater patient spending power,leading to increased usage of targeted therapies. Additionally, the prevalenceof gastric cancer in China is among the highest in the world. In 2007,approximately 392,000 cases were diagnosed in China, and it is forecasted thatthe indication population will grow 2.3 percent per year between 2007 and2012.
The report also finds that Jiangsu Simcere's Endostar and Merck KGaA'sErbitux are the targeted therapies prescribed most often by Chinese physiciansfor the treatment of gastric cancer. These new targeted therapies will beprescribed to a greater percentage of the eligible population in China than inthe past, benefiting from increased physician familiarity and better efficacyand toxicity profiles than conventional chemotherapy agents. More importantly,surveyed physicians anticipate that some targeted therapies will be includedin the National Reimbursement Drug List (NRDL) by 2012, significantlyincreasing patient accessibility to these drugs.
"The Chinese government plans to insure close to 100 percent of theChinese population by 2010 through three government-sponsored insuranceschemes: Basic Medical Insurances (BMI), Urban Resident Basic MedicalInsurance (URBMI) and new Rural Cooperative Medical Scheme (NCMS)," saidVictor Li, Ph.D., analyst at Decision Resources. "These initiatives willincrease gastric cancer diagnosis and drug-treatment rates in China andpresent an opportunity for multinational companies to reach a larger patientpopulation."
Mr. Li will be conducting a webinar entitled "China's Gastric Cancer DrugMarket to Nearly Triple by 2012: A Promising Market for Targeted Therapies"based on the report on April 24 at 10 a.m. EST. This will take an in-depthlook at the report findings and is complementary to all purchasers of thisreport. If members of the media would like to attend, please contact ElizabethMarshall at 781-296-2563 or firstname.lastname@example.org.
About Emerging Markets -- China
Emerging Markets -- China is the first and only syndicated report seriesfocusing on high-growth emerging markets with comprehensive disease-specificanalysis. With these reports, biopharmaceutical companies can accomplish thefollowing:
About Decision Resources
Decision Resources, Inc., ( http://www.decisionresources.com ) is a worldleader in healthcare market research publications, advisory services, andconsulting designed to help clients shape strategy, allocate resources, andmaster their chosen markets.
All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.-- More accurately assess the commercial opportunity for Western brands in key pharmaceutical markets of China -- Beijing, Shanghai, Guangzhou -- and in the high-growth second-tier markets of Tianjin, Wuhan, Nanjing, Hangzhou, and Jinan. -- Understand the physician treatment patterns and drivers of choice in key first- and second-tier cities based on primary research. -- Gain a clear perspective of the Chinese five-year market forecast at the drug level, broken out by urban and rural areas, and by sales from multinational and Chinese-based companies.
SOURCE Decision Resources